Twist Bioscience Corporation (TWST)

Market Cap	1.90B
Revenue (ttm)	376.57M
Net Income (ttm)	-77.67M
Shares Out	61.15M
EPS (ttm)	-1.30
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	430,373
Open	31.78
Previous Close	30.93
Day's Range	30.47 - 31.78
52-Week Range	23.30 - 55.33
Beta	2.24
Analysts	Buy
Price Target	44.63 (+43.6%)
Earnings Date	Feb 2, 2026

About TWST

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Oct 31, 2018
• Employees: 979
• Stock Exchange: NASDAQ
• Ticker Symbol: TWST
• Website: https://www.twistbioscience.com

Financial Performance

In 2025, Twist Bioscience's revenue was $376.57 million, an increase of 20.32% compared to the previous year's $312.97 million. Losses were -$77.67 million, -62.79% less than in 2024.

Analyst Summary

According to 8 analysts, the average rating for TWST stock is "Buy." The 12-month stock price target is $44.63, which is an increase of 43.60% from the latest price.

Price Target

$44.63

(43.60% upside)

Analyst Consensus: Buy